STRATA Skin Sciences, Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
SSKN Nasdaq 3840 www.strataskinsciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for STRATA Skin Sciences, Inc.

Laseroptek America Files Counterclaims Alleging Anticompetitive and Unfair Business Practices in Ongoing Litigation with Strata Skin Sciences - Feb 11th, 2026 6:00 am
STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico - Dec 9th, 2025 6:15 am
Strata Skin Sciences Inc (SSKN) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... - Nov 16th, 2025 8:00 pm
STRATA Skin (SSKN) Earnings Call Transcript - Nov 13th, 2025 3:42 pm
STRATA Skin Sciences Reports Third Quarter 2025 Financial Results and Provides a Corporate Update - Nov 13th, 2025 2:05 pm
STRATA Skin Sciences Announces CMS Recognition of Expanded CPT Codes for Inflammatory and Autoimmune Dermatologic Conditions with Company Anticipating Wider Excimer Adoption Ahead Of 2027 CPT Expansion - Nov 6th, 2025 6:00 am
STRATA Skin Sciences to Report Third Quarter 2025 Financial Results on November 13, 2025 and Provide Corporate Update - Nov 5th, 2025 6:00 am
STRATA Skin Sciences Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements - Oct 28th, 2025 6:00 am
Excimer Laser Demonstrates Promising Results in Treating Rare Variant of Cutaneous Lymphoma, Mycosis Fungoides - Oct 14th, 2025 6:15 am
Marking Eczema Awareness Month – Clinical Research Validates Strata Skin Sciences’ XTRAC® Excimer Laser as a Breakthrough Therapy for Localized Atopic Dermatitis - Oct 3rd, 2025 8:50 am
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis - Sep 30th, 2025 6:15 am
New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences’ Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach - Sep 22nd, 2025 6:15 am
STRATA Skin Sciences Announces Closing of $2.42 Million Registered Direct Offering - Sep 4th, 2025 2:05 pm
STRATA Skin Sciences’ Elevate 360 Consulting Offering Drives Growth in Partner Clinic Operations and Fuels New Partnership Agreements - Sep 4th, 2025 6:15 am
Google Gets Reprieve in Antitrust Case as US Equity Futures Turn Mixed Pre-Bell - Sep 3rd, 2025 7:08 am
STRATA Skin Sciences Announces Pricing of $2.42 Million Registered Direct Offering of Common Stock Priced At-Market Under Nasdaq Rules - Sep 3rd, 2025 6:00 am
STRATA Skin Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 2:05 pm
STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination Therapies of Its XTRAC Excimer Laser with JAK Inhibitors, Systemic and Biologic Drugs, Bolstering Expansion into New Indications Like Vitiligo and Other Auto-Immune Skin Conditions - Sep 2nd, 2025 6:05 am
Analysts Just Made A Major Revision To Their STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Revenue Forecasts - Aug 16th, 2025 6:17 am
STRATA Skin Sciences Second Quarter 2025 Earnings: Misses Expectations - Aug 15th, 2025 4:39 am